This invention relates to benzodiazepine derivatives, compositions comprisingtherapeutically effective amounts ofthose benzodiazepine derivatives and methods of using those derivatives orcompositions in treating cognitive impairment associatedwith central nervous system (CNS) disorders. In particular, it relates to theuse of a .alpha.5- containing GABA A receptor agonist (e.g., a.alpha.5-containing GABA A receptor positive allosteric modulator) asdescribed herein in treating cognitive impairment associated withcentral nervous system (CNS) disorders in a subject in need or at riskthereof, including, without limitation, subjects having or at riskfor age-related cognitive impairment, Mild Cognitive Impairment (MCI),amnestic MCI (aMCI), Age- Associated Memory Impairment(AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer sDisease(AD), prodromal AD, post traumatic stressdisorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateralsclerosis (ALS), cancer-therapy-related cognitive impairment,mental retardation, Parkinson' s disease (PD), autism spectrum disorders,fragile X disorder, Rett syndrome, compulsive behavior,and substance addiction.
